Articles by Daniel Marsh
Pharvaris Surges 17% as Phase 3 HAE Trial Meets Primary Endpoint
Pharvaris (PHVS) soared 17% after its oral HAE preventive met the primary endpoint in Phase 3, reducing monthly attacks by 83% versus placebo.
Eaton Stock Rises on UBS Upgrade, $515 Target Hinges on Margin Expansion
UBS upgrades Eaton to Buy with a $515 target, citing strong backlog and margin expansion potential. Shares rise 3% in premarket trading.
Bloom Energy Soars on S&P 500 Inclusion; Valuation at 99x Earnings
Bloom Energy stock surges 5.8% premarket on S&P 500 inclusion, but the stock's 99x forward earnings multiple raises valuation concerns despite strong AI-driven growth.
NAB Stock Dips 1.4% as RBA Rate Hike Dilemma Weighs on Banks
NAB shares fell 1.4% to A$38.87 as Westpac forecast another RBA hike, which could lift deposit earnings but also dampen loan demand and credit quality.
Intel's High-NA Milestone: 1M Wafers, But Revenue Gap Looms
Intel's High-NA EUV milestone of 1 million wafers proves technical progress, but external foundry revenue is a mere $293M. The market watches for customer wins.
Rivian's Software Upgrade: A Strategic Move That Doesn't Yet Solve Cash Flow Woes
Rivian's RivianOS 2 update is a strategic step, but RIVN stock still faces an $849 million cash-flow test. The software must cut costs and boost subscriptions, not just improve the interface.
Novartis Shares Plunge 9% as Key Drug Trial Misses Goal
Novartis shares tumbled 9% after its lead Avidity drug failed a pivotal trial, erasing about $22 billion in value and raising doubts about its pipeline.
PG&E's $2B Capex Deferral: A Bid to Cut Debt That Could Cap Growth
PG&E defers $2B in 2027 capex to cut debt, trading at 7.9x forward earnings. The move lowers financial risk but slows growth, as wildfire policy remains unresolved.
Headlam's Frozen Equity: CVA Plan Leaves Shareholders in Limbo
Headlam Group's shares stay suspended at 10.5p while administrators pursue a CVA and refinancing, but the plan offers no terms for existing shareholders, leaving equity value uncertain.
Renalytix Shares Rebound 36% on Recapitalization Plan
Renalytix shares jumped 36% on AIM resumption after a £10.48M capital raise and debt conversion, but existing holders face 35% dilution.
Rolls-Royce's £20 Target: A $5.3B Cash Flow Hurdle
Rolls-Royce shares near 1,473p; a £20 target implies ~£5.3B annual free cash flow, 36% above 2026 guidance. Buybacks help, but operating performance is key.
Nintendo Shares Unchanged Ahead of Zelda Direct, Ocarina of Time Confirmed for Switch 2
Nintendo shares closed unchanged at ¥8,750 despite confirming Ocarina of Time for Switch 2 in 2026. The market awaits the Zelda Direct for product details.